JP7798361B2 - デキストロメトルファンの経皮送達 - Google Patents

デキストロメトルファンの経皮送達

Info

Publication number
JP7798361B2
JP7798361B2 JP2022559484A JP2022559484A JP7798361B2 JP 7798361 B2 JP7798361 B2 JP 7798361B2 JP 2022559484 A JP2022559484 A JP 2022559484A JP 2022559484 A JP2022559484 A JP 2022559484A JP 7798361 B2 JP7798361 B2 JP 7798361B2
Authority
JP
Japan
Prior art keywords
dextromethorphan
weight
subject
day
transdermal patch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022559484A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519959A (ja
JP2023519959A5 (cg-RX-API-DMAC7.html
Inventor
スレシュ ボルサディア
カルパナ パテル
ホック エス. タン
クルナル ラバル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shinkei Therapeutics Inc
Original Assignee
Shinkei Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shinkei Therapeutics Inc filed Critical Shinkei Therapeutics Inc
Publication of JP2023519959A publication Critical patent/JP2023519959A/ja
Publication of JP2023519959A5 publication Critical patent/JP2023519959A5/ja
Application granted granted Critical
Publication of JP7798361B2 publication Critical patent/JP7798361B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022559484A 2020-03-30 2021-03-29 デキストロメトルファンの経皮送達 Active JP7798361B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063001607P 2020-03-30 2020-03-30
US63/001,607 2020-03-30
PCT/US2021/024572 WO2021202329A1 (en) 2020-03-30 2021-03-29 Transdermal delivery of dextromethorphan

Publications (3)

Publication Number Publication Date
JP2023519959A JP2023519959A (ja) 2023-05-15
JP2023519959A5 JP2023519959A5 (cg-RX-API-DMAC7.html) 2024-04-03
JP7798361B2 true JP7798361B2 (ja) 2026-01-14

Family

ID=77928529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559484A Active JP7798361B2 (ja) 2020-03-30 2021-03-29 デキストロメトルファンの経皮送達

Country Status (10)

Country Link
US (1) US20240216358A1 (cg-RX-API-DMAC7.html)
EP (1) EP4125902A4 (cg-RX-API-DMAC7.html)
JP (1) JP7798361B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220161416A (cg-RX-API-DMAC7.html)
CN (1) CN115996709A (cg-RX-API-DMAC7.html)
AU (1) AU2021249031A1 (cg-RX-API-DMAC7.html)
CA (1) CA3173322A1 (cg-RX-API-DMAC7.html)
IL (1) IL296624A (cg-RX-API-DMAC7.html)
TW (1) TW202203921A (cg-RX-API-DMAC7.html)
WO (1) WO2021202329A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12569479B2 (en) 2016-05-25 2026-03-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
CN122440635A (zh) 2020-12-01 2026-07-24 安泰赛普生物风投二代有限责任公司 用于降低抑郁症患者的自杀风险的安非他酮和右美沙芬
IT202100029225A1 (it) * 2021-11-18 2023-05-18 Capietal Italia S R L Miscela comprendente un cannabidiolo CBD, un beta-cariofillene BCP e un furanodiene, per uso in un metodo di trattamento del dolore neuropatico periferico
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US12156914B2 (en) 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
US12194036B2 (en) 2022-07-07 2025-01-14 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11844797B1 (en) 2023-04-20 2023-12-19 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
WO2024077133A1 (en) * 2022-10-06 2024-04-11 Shinkei Therapeutics, Inc. Transdermal delivery of dextromethorphan
KR20250114110A (ko) 2022-11-28 2025-07-28 안테씨프 바이오벤쳐스 투 엘엘씨 약물 활성의 조절제로서의 부프로피온
CN119700641A (zh) * 2025-02-26 2025-03-28 深圳市药欣生物科技有限公司 舌下施用的右美沙芬药物组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019070864A1 (en) 2017-10-04 2019-04-11 Shinkei Therapeutics Llc DEVICE FOR TRANSDERMAL DEXTROMETHORPHAN DELIVERY

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE194281T1 (de) * 1994-09-14 2000-07-15 Minnesota Mining & Mfg Matrix für transdermale wirkstofffreisetzung
SE9601528D0 (sv) * 1996-04-23 1996-04-23 Pharmacia Ab Transdermally administered dextromethorphan as antitissue agent
US5985317A (en) * 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
CA2289190A1 (en) * 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
US8058291B2 (en) * 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US20060223786A1 (en) * 2005-04-01 2006-10-05 Smith David J Transdermal pain control method and device
CA2729346A1 (en) * 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
CA2815898C (en) * 2010-11-17 2018-12-18 Hexal Ag Transdermal therapeutic system comprising buprenorphine
US12144899B2 (en) * 2018-04-25 2024-11-19 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019070864A1 (en) 2017-10-04 2019-04-11 Shinkei Therapeutics Llc DEVICE FOR TRANSDERMAL DEXTROMETHORPHAN DELIVERY

Also Published As

Publication number Publication date
TW202203921A (zh) 2022-02-01
JP2023519959A (ja) 2023-05-15
KR20220161416A (ko) 2022-12-06
CA3173322A1 (en) 2021-10-07
WO2021202329A1 (en) 2021-10-07
EP4125902A1 (en) 2023-02-08
EP4125902A4 (en) 2024-05-22
US20240216358A1 (en) 2024-07-04
CN115996709A (zh) 2023-04-21
AU2021249031A1 (en) 2022-11-10
IL296624A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
JP2023519959A (ja) デキストロメトルファンの経皮送達
JP7609943B2 (ja) デキストロメトルファン経皮送達デバイス
JP2023519959A5 (cg-RX-API-DMAC7.html)
CN110913844A (zh) 用于氯胺酮的透皮药物递送系统
JP2023500606A (ja) テトラベナジン経皮送達デバイス
JP2025532367A (ja) デキストロメトルファンの経皮送達
CN109310526B (zh) 普拉克索经皮贴片系统与用法
RU2795729C2 (ru) Устройство для трансдермальной доставки декстрометорфана
HK40129313A (en) Transdermal delivery of dextromethorphan
HK40028806A (en) Dextromethorphan transdermal delivery device
HK40028806B (en) Dextromethorphan transdermal delivery device
JP2022532635A (ja) 高含量のドネペジル又はその塩を含む経皮吸収製剤
TWI757253B (zh) 普拉克索經皮貼片系統與用法
CA3003460C (en) Pramipexole transdermal delivery system and uses thereof
HK40025664A (en) Transdermal drug delivery system for ketamine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221005

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250930

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251218

R150 Certificate of patent or registration of utility model

Ref document number: 7798361

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150